Peptides Clarified

Recovery & performance

BPC-157

Also known as: Body Protection Compound 157, pentadecapeptide BPC 157

Not FDA-approvedEvidence: Preclinical only

Plain-language summary

A synthetic 15-amino-acid peptide marketed for tissue healing and recovery. It is not FDA-approved for any use, and human clinical evidence is essentially absent.

Regulatory status

Compounded and unapproved products are not FDA-reviewed for safety, effectiveness, or quality.

Evidence snapshot

Preclinical only. Evidence comes from laboratory or animal studies. Effects in humans are unproven.

How it works

Proposed to promote angiogenesis and tissue repair and to modulate growth-factor pathways, based mainly on rodent studies; its mechanism and effects in humans are not established.

Approved uses and researched uses

FDA-approved uses

None. This product has no FDA-approved use for the context described.

Researched (not approved) uses

  • Tendon, ligament, and muscle healing (animal studies)
  • Gastrointestinal ulcer healing (animal studies)

Researched uses are studied but not FDA-approved and may be off-label. This is not a recommendation to use them.

Known risks and uncertainties

Human safety data are lacking, so long-term risks are unknown. Because it is sold outside FDA oversight, products may be contaminated, mislabeled, or of uncertain purity and dose. Effects on tumor growth via angiogenesis are theoretically concerning and unstudied in people.

Cautions and contraindications

No established clinical guidance. Absence of human trials means no defined contraindicated populations; caution is warranted especially for anyone with cancer history given angiogenic effects, and it is banned in some sports contexts.

Consumer considerations

  • Not FDA-approved; marketed products are unregulated and unverified.
  • Human efficacy and safety have not been demonstrated in controlled trials.
  • Its 503A compounding status is contested and shifting; being "available" is not the same as being approved.
  • It is prohibited by the World Anti-Doping Agency for athletes.
  • Product purity and actual contents cannot be assumed.

Questions to ask a licensed clinician

  • What human evidence, if any, supports using this for my situation?
  • What are the unknown long-term and cancer-related safety concerns?
  • Is obtaining or using this legal and appropriate given its regulatory status?
  • Are there FDA-approved alternatives for my injury or condition?
  • How would we monitor for adverse effects given the lack of data?

Sources

Primary and authoritative sources

  1. 1.Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
  2. 2.Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
Last reviewed (yesterday)

Reviewed by Peptides Clarified Editorial — Editorial sourcing review — licensed clinical review pending.